Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety and Efficacy of IB1001 in Severe Hemophilia B
2013-003742-16Phase 3Terminated
- Sponsor
- Cangene Corporation
- Start
- Sep 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trenonacog alfa in hemophilia B (HB), sponsored by Cangene Corporation. Primary endpoint: Pharmacokinetics of IB1001. Started Sep 2013; status: terminated.
02
Drugs
trenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2013-003742-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003742-16.